Biogen Inc (BIIB)

BIIB (NASDAQ:Drugs) EQUITY
$429.87
pos +0.00
+0.00%
Today's Range: 429.36 - 436.67 | BIIB Avg Daily Volume: 1,899,100
Last Update: 03/27/15 - 4:00 PM EDT
Volume: 0
YTD Performance: 26.64%
Open: $0.00
Previous Close: $428.93
52 Week Range: $272.02 - $480.18
Oustanding Shares: 234,614,474
Market Cap: 100,633,186,333
6-Month Chart
TheStreet Ratings Grade for BIIB
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 10 12 12 11
Moderate Buy 1 1 1 1
Hold 5 4 4 5
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.69 1.53 1.53 1.65
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 34.68
Price Earnings Comparisons:
BIIB Sector Avg. S&P 500
34.68 34.70 27.26
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
25.55% 38.78% 240.54%
GROWTH 12 Mo 3 Yr CAGR
Revenue 46.50 0.92 0.24
Net Income 57.90 1.32 0.32
EPS 58.30 1.44 0.34
Earnings for BIIB:
EBITDA 3.41B
Revenue 8.51B
Average Earnings Estimates
Qtr (03/15) Qtr (06/15) FY (12/15) FY (12/16)
Average Estimate $3.96 $4.09 $16.88 $19.95
Number of Analysts 2 2 2 2
High Estimate $3.96 $4.09 $16.94 $20.26
Low Estimate $3.96 $4.08 $16.81 $19.65
Prior Year $2.45 $3.49 $13.79 $16.88
Growth Rate (Year over Year) 61.63% 17.05% 22.37% 18.25%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Here are healthcare stocks of all shares and sizes with strong charts.
But wait for a pullback before getting in.
Good buys kept getting overlooked.

How I Play the Biotechs Real Money Pro($)

A strategy to immunize biotech investors from regret.
Its Alzheimer's treatment impressed, but dosing questions remain.
If it doesn't heat up, traders may start selling more aggressively.
Bearish
Mar 23, 2015 | 7:08 AM EDT
BIIB was downgraded from Buy to Hold, Stifel Said. Valuation call, as some potential risks loom on the horizon.     
Own them, or take something off the table?
It was encouraging to see the market broaden out like this.
I really like the stocks. But I also like making money on stocks.

Columnist Conversations

Google rallied off its 2012 low making a series of higher highs and higher lows for two years. The pullback to...
Cover story in Barrons: "JPMorgan Rising" - JPM was added to my Best Ideas List and "Trade of the Week" on Wed...

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.